| website | https://mushmail.org |
The Future Of Psychedelics In Psychiatry: A Neurologist Explains
"Results like these have led to increased excitement about psychedelics and contributed to researchers speculating that positive clinical trial results could lead to FDA approval within a year. This is a big deal."
#Psilocybin #psilocybintherapy
#psychedelictherapy
#psychedelics #psychedelic #magicmushrooms
Making Waves--A Psychedelic Update
https://www.bereskinparr.com/doc/making-waves-a-psychedelic-update
"...how Canada, the United States (US) and the European Union (EU) are regulating such drugs and are allowing them to be used in clinical trials."
#Psilocybin #psilocybintherapy
#psychedelictherapy
#magicmushrooms
#psychedelics #psychedelic
Research on Psilocybin and Depression – A Real Solution?
https://www.medsnews.com/health/research-on-psilocybin-and-depression-a-real-solution/
"Flattening the peaks in the mental landscape helps break unhealthy thought patterns, one of the main symptoms that manifest as depression."
#Psilocybin #psilocybinresearch #psilocybintherapy #magicmushrooms #psychedelictherapy #psychedelictreatments #psychedelicresearch
Psychedelic treatments are speeding towards approval — but no one knows how they work
https://www.nature.com/articles/d41586-023-03334-6
"...most scientists do think that psychedelic drugs promote brain plasticity, enabling the dendrites and axons that form neural circuits to diversify and make new connections."
#Psilocybin #psychedelictherapy #psychedelictreatments #magicmushrooms #psychedelic #psilocybinresearch #psilocybintherapy
Psilocybin and SSRIs: A Talk with Dr. Erica Zelfand, ND
https://psychedelic.support/resources/psilocybin-and-ssris
"Anecdotal evidence, along with one recent clinical trial, suggests that it’s safe to combine psilocybin with SSRIs."
- Psychedelic.Support, April, 2023
#Psilocybin #magicmushrooms #psilocybinresearch #psilocybinmushrooms #psilocybins #psychedelicmushrooms #psychedelictherapy #psychedelics
#psilocybintherapy
Duke Researchers Probe the Magic of Psychedelics as Medicine
https://medschool.duke.edu/stories/duke-researchers-probe-magic-psychedelics-medicine
“Do you need that psychedelic experience to achieve therapeutic effects? Or are you just putting a key in a biochemical lock, and it doesn’t matter if you’re conscious or not?"
#Psilocybin #magicmushrooms #psilocybinresearch #psilocybinmushrooms #psychedelictherapy #psychedelics
The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin ...
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
https://www.nature.com/articles/s41386-023-01648-7
"..., post-hoc analyses revealing correlations between the intensity of altered or mystical state of consciousness and therapeutic outcome suggest that the acute psychedelic experience may play an important role."
--(published July, 2023)
#Psilocybin #magicmushrooms #psilocybinlover #psilocybinresearch #psilocybinmushrooms #psychedelictherapy #psychedelics
Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect. This phase II, exploratory, international, fixed-dose, open-label study explored the safety, tolerability, and efficacy of a synthetic form of psilocybin (investigational drug COMP360) adjunct to a selective serotonin reuptake inhibitor in participants with TRD. Participants received a single 25 mg dose of psilocybin alongside psychological support and were followed-up for 3 weeks. The primary efficacy end point was change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from Baseline at Week 3. Secondary end points were safety, including treatment-emergent adverse events (TEAEs), the proportion of responders and remitters at Week 3, and the change from Baseline to Week 3 in Clinical Global Impression–Severity (CGI-S) score. Nineteen participants were dosed and the mean Baseline MADRS total score was 31.7 (SD = 5.77). Twelve (63.2%) participants had a TEAE, most of which were mild and resolved on the day of onset. There were no serious TEAEs or indication of increased suicidal ideation or behavior. At Week 3, mean change from Baseline in MADRS total score was −14.9 (95% CI, −20.7 to −9.2), and −1.3 (SD = 1.29) in the CGI-S. Both response and remission were evident in 8 (42.1%) participants. Larger, comparator-controlled trials are necessary to understand if this paradigm can optimize treatment-outcome where antidepressant drug withdrawal would be problematic.
BC Info Bot
PlanetMedicines